https://www.pharmafocusasia.com/technotrends/breakthrough-gedatolisib-therapy-discovered-for-the-treatment
Breakthrough Gedatolisib Therapy Discovered for the Treatment of Metastatic Breast Cancer
Celcuity Inc discovered Gedatolisib new therapy for the treatment of HR+/HER2- Metastatic Breast Cancer. Gedatolisib, the first-in-class pan-PI3K/mTOR...
metastatic breast cancerfor thebreakthroughgedatolisibtherapy
https://www.biospace.com/celcuity-inc-announces-plan-to-initiate-a-phase-3-clinical-trial-for-gedatolisib-as-first-line-treatment-for-hr-her2-advanced-breast-cancer-and-secures-approximately-62-million-debt-financing
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line...
Jul 30, 2024 - Celcuity Inc. announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line...
clinical trialfirst lineincannouncesplan
https://ogkologos.com/adding-gedatolisib-to-fulvestrant-with-or-without-palbociclib-improves-pfs-in-patients-with-hr-positive-her2-negative-pik3ca-wild-type-abc/
Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with...
in patientsaddinggedatolisibwithoutpalbociclib